The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback